EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy

Qi‐Song Tong, Na Shu, Hua Huang, Wei Xu, Wen‐Chuan Xie, Quan Xia, Jin‐Zhi Du

Aggregate · 2026-05 · 7 (5)

DOI: 10.1002/agt2.70353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aggregate, online erschienen am 29.04.2026. Verfasst von Qi‐Song Tong und 6 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, University Natural Science Research Project of Anhui Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In situ vaccination is a promising strategy for personalized cancer immunotherapy; however, its efficacy is often limited by rapid antigen degradation, inefficient delivery to lymph nodes (LNs), and the immunosuppressive tumor microenvironment (TME). To overcome these challenges, we developed a versatile in situ cancer nanovaccine by conjugating the TLR7/8 agonist R848 to a polymeric immunogenic cell death (ICD) inducer, termed G4P‐C7A‐R848. In aqueous solution, G4P‐C7A‐R848 self‐assembles into nanoparticles (PCR‐NPs), which accumulate at tumor sites following systemic administration. Within tumors, PCR‐NPs trigger the release of tumor‐associated antigens from tumor cells via ICD and subsequently capture them to form an in situ nanovaccine. These nanovaccines then traffic to tumor‐draining LNs (TDLNs), where they promote dendritic cell maturation and T cell activation. Moreover, the nanovaccine reprograms macrophages toward the tumoricidal M1 phenotype, thereby alleviating immunosuppression in the TME. This coordinated action enhances the infiltration and activation of CD8 + T cells, leading to robust and durable antitumor immunity. Across multiple murine tumor models, PCR‐NPs treatment resulted in significant tumor regression and prolonged survival. This study offers a simple yet effective platform for developing potent in situ cancer vaccines.

Förderung

  • National Natural Science Foundation of China
  • University Natural Science Research Project of Anhui Province

Zitieren

APA

Tong, Q., Shu, N., Huang, H., Xu, W., Xie, W., Xia, Q., & Du, J. (2026). A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy. Aggregate, 7(5). https://doi.org/10.1002/agt2.70353

Vancouver

Tong Q, Shu N, Huang H, Xu W, Xie W, Xia Q, et al. A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy. Aggregate. 2026;7(5). doi:10.1002/agt2.70353

BibTeX
@article{Tong2026,
  author = {Tong, Qi‐Song and Shu, Na and Huang, Hua and Xu, Wei and Xie, Wen‐Chuan and Xia, Quan and Du, Jin‐Zhi},
  title = {A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy},
  journal = {Aggregate},
  year = {2026},
  volume = {7},
  number = {5},
  doi = {10.1002/agt2.70353}
}
Kostenlos starten →